GFAP and Alzheimer disease: Between group differences in plasma biomarker concentrations demonstrated that participants with AD had roughly 2-fold higher plasma concentrations of pTau181, NfL, and GFAP compared to CN, while tTau concentrations on average were 1.5-fold higher in AD (p < 0.001 for all comparisons; Figure 3, Table 4).